Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary EDAP TMS Pre-Announces Strong 98% Growth in HIFU sales in the Second Quarter 2019
45% growth in total Q2 2019 revenue year-over-year   78% growth in HIFU sales year-to-date through June 30, 2019   Company to Report Second Quarter 2019 Financial Results on Wednesday, August 28, 2019 and to host conference call and webcast on Thursday August 29 , at 8:30 am EDT LYON, France , July
View HTML
Toggle Summary Edap Tms: EDAP Announces Positive Outcome from CPT Panel for HIFU Reimbursement in the U.S.
AMA allocates a new Category 1 CPT code for High Intensity Focused Ultrasound (HIFU)   Definitive CPT code will cover the transrectal ablation of malignant prostate tissue with HIFU including ultrasound guidance LYON, France , June 10, 2019 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”) , the global
View HTML
Toggle Summary EDAP Reports 2019 First Quarter Results
EDAP Reports 2019 First Quarter Results HIFU revenue growth of 58.6% year-over-year Profitable for second consecutive quarter Total Q1 revenues of EUR 10.1 million ; strongest Q1 to date Improved Q1 gross profit margin by 4.2 percentage points vs prior year LYON, France , May 15, 2019 -- EDAP TMS
View HTML
Toggle Summary EDAP TMS SA to Announce First Quarter 2019 Financial Results on Wednesday, May 15, 2019
Company to host conference call and webcast on Thursday, May 16 , at 8:30 am EDT LYON, France , May 2, 2019  -  EDAP TMS SA  (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the first quarter ended March 31, 2019 after the
View HTML
Toggle Summary EDAP TMS SA : EDAP to Showcase Suite of Therapeutic Ultrasound Products During the American Urology Association Annual Meeting
EDAP to Provide Live Demonstrations and Host Q&A with Interested Parties at Booth #2211 LYON , France, April 29, 2019 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that it will demonstrate the capabilities of its range of minimally-invasive therapeutic
View HTML
Toggle Summary EDAP TMS SA : EDAP Reports Q4 and Full Year 2018 Results
Reports record revenues for the fifth consecutive year Record fiscal year 2018 revenues of €39.2 million Q4 2018 HIFU net sales increased 79% year-over-year Profitable and cash flow positive during the fourth quarter of 2018 Completed first U.S. sale of Focal One at the end of 2018 Ended the year
View HTML
Toggle Summary EDAP TMS SA : University of Chicago Medicine Becomes First Hospital in the Midwest to Acquire Breakthrough Focal One® HIFU Advanced Robotic Technology for Prostate Cancer Treatment
Focal One's precision means qualifying prostate cancer patients can forego prostate removal surgery and avoid life-altering side effects including incontinence and impotence LYON, France - April 1, 2019 - EDAP TMS SA (Nasdaq: EDAP) , the global leader in therapeutic ultrasound, today announced that
View HTML
Toggle Summary EDAP TMS SA : EDAP TMS SA to Announce Fourth Quarter and Fiscal Year 2018 Financial Results on Monday, April 1, 2019
Company to host conference call and webcast on Tuesday, April 2 at 8:30am EDT LYON , France, March 21, 2019  -  EDAP TMS SA  (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced that it will release its financial results for the fourth quarter and year ended December 31,
View HTML
Toggle Summary EDAP TMS SA : HIFU Pioneer Houston Methodist Hospital Acquires EDAP's Next Generation Focal One HIFU System
    Houston Methodist's Upgrade from Ablatherm to Focal One Reinforces EDAP's Position as a Leading HIFU Innovator LYON, France , March 4, 2019 -- EDAP TMS SA (Nasdaq: EDAP) -- Houston Methodist Hospital , one of the first hospitals in the U.S. to offer Ablatherm® Robotic High Intensity Focused
View HTML
Toggle Summary EDAP TMS SA : UCI Health Medical Center Becomes First in the U.S. to Treat Patients Using EDAP's Breakthrough Focal One® HIFU Technology
UC I Health , one of the three US medical centers to acquire EDAP's Focal One device, is a recognized leader in prostate cancer diagnosis and treatment utilizing robot-assisted and minimally invasive technologies LYON, France , February 5 , 2019 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the
View HTML